Bloomberg -- Sanofi-Aventis SA’s patent on the blood-thinner Plavix will be reconsidered by the U.S. Patent and Trademark Office to determine if it should have been issued, according to information on the agency’s Web site.
Bloomberg -- Sanofi-Aventis SA’s patent on the blood-thinner Plavix will be reconsidered by the U.S. Patent and Trademark Office to determine if it should have been issued, according to information on the agency’s Web site.
